SlideShare a Scribd company logo
Journal Reading
Presenter: FM R2盧敬文
Supervisor: VS 何宗錦
2020.02.14
• vaginal microbiota (VMB)
• vaginal dysbiosis
• bacterial vaginosis (BV)
characterized by a reduction of lactobacilli and an increase of other anaerobes
• bacterial pathobionts
(Proteobacteria, streptococci, staphylococci, and enterococci)
• Candida albicans
• Trichomonas vaginalis
• Vaginal dysbiosis  pelvic inflammatory disease, HIV acquisition, and
adverse pregnancy outcomes.
• BV is diagnosed by:
Nugent scoring of vaginal Gram stains
or by the Amsel criteria.
• BV is treated with antibiotics
• recurrence rates are high
https://en.wikipedia.org/wiki/Nugent_score
• Metronidazole is a nitroimidazole class drug.
• Culture studies have shown that lactobacilli are not sensitive to
metronidazole.
High recurrence rate?
• Hypothesized:
due to vaginal mucosal biofilm formation
by G. vaginalis and other BV-associated anaerobes
Materials and Methods
• Rinda Ubuzima research clinic in Kigali, Rwanda, in 2015
• women at high risk of BV/T. vaginalis
• in the last 12 months
• more than 1 sex partner
• having been treated for BV and/or a sexually transmitted infection
• BV-positive and/or T. vaginalis -positive
• treated with 7 days of 500 mg generic oral metronidazole, BID
• Posttreatment visit within 3 days after treatment completion
Diagnostic procedures
• BV was diagnosed by
• Gram stain Nugent scoring
a score of 0-3 was considered optimal,
4-6 intermediate microbiota,
and 7-10 BV
• modified Amsel criteria
defined as the presence of 2/3 criteria:
• vaginal pH >4.5
• positive whiff test
• and/or > 20% clue cells
黃珮茹、林益卿。常見陰道炎診斷與治療。家庭醫學與基層醫療。第三十一卷,第五期。
Molecular VMB testing
• DNA was extracted from 1 swab per woman per visit
• The V3-V4 region of 16S rRNA genes were amplified and sequenced
• The panbacterial 16S rRNA gene copy concentration per sample was
determined
http://www.yourgene.com.tw/content/messagess/contents/655643254701452640/
16S 核糖體 RNA (16S rRNA) 在演化過程中,改變的程度相當
的低,大多數 16S rRNA 其中有 V1~V9 共 9 個高度變異區域
(High Variable Regions,HVRs)
透過選擇其中高變區的序列,進行 PCR 專一性增幅放大,
經過定序,將序列作為分類與鑑定環境或生物體內微生物
之種類與群落
Statistical analyses
• VMB characteristics pre- and posttreatment were compared
• all women (N=68),
• women stratified by treatment success/failure(n=55)
• Pretreatment C. trachomatis/N. gonorrhoeae status(N=67)
• Received another antibiotic in addition to metronidazole at the pretreatment
visit or not (N=68)
• having reported unusual vaginal discharge pretreatment or not(N=68)
Ethical statement
• Written informed consent provided
• approved by the National Ethics Committee of Rwanda
• and the University of Liverpool Research Ethics Subcommittee for
Physical Interventions.
Results
Results
82.4%: BV alone
2.9%: T. vaginalis alone
14.7%: both BV and T. vaginalis
38.2%: Ongoing C. trachomatis
and/or N. Gonorrhoeae infection
mean bacterial group relative abundances
Pre- and posttreatment
16S microbiota data
shift toward
increased relative
abundance of
lactobacilli
 decreased relative
abundances of several
BV anaerobes
Total bacterial concentration Total lactobacilli
Total BV-anaerobes Total pathobionts
But interindividual variability was high
Most
variability
• Participants with treatment failure as defined by Nugent scoring
• posttreatment
Lower mean lactobacilli relative abundance,
smaller decreases in mean total bacteria and BV-anaerobes concentrations,
less often a lactobacilli-dominated VMB type,
• pretreatment
Greater mean pathobionts concentration
• Successfully treated participants:
significant decreases in the mean concentrations of all 8 common BV
anaerobes
• unsuccessfully treated participants:
not decreases in G. vaginalis and BVAB1
• not identify any statistically significant sociodemographic or biological
correlates of treatment failure
• except for pathobionts concentration pretreatment
Discussion
• cure rate of 7-day oral metronidazole treatment by Nugent scoring
only 54.5%.
• Treatment failure associated with:
• greater levels of pretreatment Gardnerella vaginalis or pathobionts
• not with sociodemographic factors.
• unknown which concentrations of which pathobionts in the vagina
should be treated to prevent complications
• metronidazole treatment
 not change the pathobionts concentration
 increase the relative abundance
• Greater pretreatment pathobionts concentration
 increased likelihood of treatment failure
Results of the study in context of what is known
• The extent of BV-anaerobes reduction was more modest than
expected
• lactobacilli are not sensitive to Metronidazole
• Women with a pretreatment VMB type containing a relative
abundance of >50% G. vaginalis, compared with <50%
more likely to continue to have a dysbiotic VMB type posttreatment
• CRISPR-genes may protect the bacteria against metronidazole.
Research and clinical implications
• vaginal biofilm disrupting treatment?
• adjuvant therapy with lactobacilli-based live biotherapeutics?
• treatment with drugs that specifically target all G. vaginalis clades?
• diagnostic tests to determine
the presence of a biofilm
or concentrations of G. vaginalis
 are not yet available
Strengths and limitations of the study
• limited generalizability of the results
to lower risk and non-African populations
• lack of vaginal biofilm detection
• Strength: used multiple laboratory and analytic methods
黃珮茹、林益卿。常見陰道炎診斷與治療。家庭醫學與基層醫療。第三十一卷,第五期。
Thank you
for
your attention.
https://www.flickr.com/photos/lksriv/9413310222/

More Related Content

Similar to Gyn bv 20200214: Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure

Sexually transmitted infections in pregnancy
Sexually transmitted infections in pregnancySexually transmitted infections in pregnancy
Sexually transmitted infections in pregnancy
mamta rai
 
Bv dalam kehamilan
Bv dalam kehamilanBv dalam kehamilan
Bv dalam kehamilan
Sofie Krisnadi
 
Relay Tutorials : Bacterial Vaginosis update
Relay Tutorials : Bacterial Vaginosis updateRelay Tutorials : Bacterial Vaginosis update
Relay Tutorials : Bacterial Vaginosis update
AkankshaTripathi43
 
Vaginal Discharge
Vaginal DischargeVaginal Discharge
Vaginal Discharge
Monypech Norng
 
Vaginitis
VaginitisVaginitis
Genitourinary infections and sexually transmitted diseases
Genitourinary infections and sexually transmitted diseasesGenitourinary infections and sexually transmitted diseases
Genitourinary infections and sexually transmitted diseases
mauricio marin
 
BACTERIAL VAGINOSIS final.pptx
BACTERIAL VAGINOSIS final.pptxBACTERIAL VAGINOSIS final.pptx
BACTERIAL VAGINOSIS final.pptx
LahariNaidu7
 
vaginal discharge
vaginal dischargevaginal discharge
vaginal discharge
dr.hafsa asim
 
Vulvovaginitis2
Vulvovaginitis2Vulvovaginitis2
Vulvovaginitis2
Israel vasquez
 
Infections of the Genital Tract - Part II
Infections of the Genital Tract - Part IIInfections of the Genital Tract - Part II
Infections of the Genital Tract - Part II
Helen Madamba
 
CHRONIC VIRAL HEPATITIS combined.pptx
CHRONIC VIRAL HEPATITIS combined.pptxCHRONIC VIRAL HEPATITIS combined.pptx
CHRONIC VIRAL HEPATITIS combined.pptx
ssuser0e95b9
 
Hiv and infertility
Hiv and infertilityHiv and infertility
Hiv and infertility
Neelam Ohri
 
HIV and Infertility
HIV and InfertilityHIV and Infertility
HIV and Infertility
Neelam Ohri
 
Vaginitis
VaginitisVaginitis
Vaginitis
Mamdouh Sabry
 
Vaginal discharge
Vaginal dischargeVaginal discharge
Vaginal discharge
bausher willayat
 
Vaginal Discharge
Vaginal DischargeVaginal Discharge
Vaginal Discharge
ssnsharifa
 
BACTERIAL VAGINOSIS 2021 ppt.pptx
BACTERIAL VAGINOSIS 2021 ppt.pptxBACTERIAL VAGINOSIS 2021 ppt.pptx
BACTERIAL VAGINOSIS 2021 ppt.pptx
ssuserfa7ef6
 
Development of monoclonal antibodies Workshop
Development of monoclonal antibodies WorkshopDevelopment of monoclonal antibodies Workshop
Development of monoclonal antibodies Workshop
Angel Hernández
 
Pid by dr shabnam naz
Pid by dr shabnam nazPid by dr shabnam naz
Pid by dr shabnam naz
dr shabnam naz shaikh
 
Hiv in pregnancy
Hiv in pregnancyHiv in pregnancy
Hiv in pregnancy
Archana Verma
 

Similar to Gyn bv 20200214: Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure (20)

Sexually transmitted infections in pregnancy
Sexually transmitted infections in pregnancySexually transmitted infections in pregnancy
Sexually transmitted infections in pregnancy
 
Bv dalam kehamilan
Bv dalam kehamilanBv dalam kehamilan
Bv dalam kehamilan
 
Relay Tutorials : Bacterial Vaginosis update
Relay Tutorials : Bacterial Vaginosis updateRelay Tutorials : Bacterial Vaginosis update
Relay Tutorials : Bacterial Vaginosis update
 
Vaginal Discharge
Vaginal DischargeVaginal Discharge
Vaginal Discharge
 
Vaginitis
VaginitisVaginitis
Vaginitis
 
Genitourinary infections and sexually transmitted diseases
Genitourinary infections and sexually transmitted diseasesGenitourinary infections and sexually transmitted diseases
Genitourinary infections and sexually transmitted diseases
 
BACTERIAL VAGINOSIS final.pptx
BACTERIAL VAGINOSIS final.pptxBACTERIAL VAGINOSIS final.pptx
BACTERIAL VAGINOSIS final.pptx
 
vaginal discharge
vaginal dischargevaginal discharge
vaginal discharge
 
Vulvovaginitis2
Vulvovaginitis2Vulvovaginitis2
Vulvovaginitis2
 
Infections of the Genital Tract - Part II
Infections of the Genital Tract - Part IIInfections of the Genital Tract - Part II
Infections of the Genital Tract - Part II
 
CHRONIC VIRAL HEPATITIS combined.pptx
CHRONIC VIRAL HEPATITIS combined.pptxCHRONIC VIRAL HEPATITIS combined.pptx
CHRONIC VIRAL HEPATITIS combined.pptx
 
Hiv and infertility
Hiv and infertilityHiv and infertility
Hiv and infertility
 
HIV and Infertility
HIV and InfertilityHIV and Infertility
HIV and Infertility
 
Vaginitis
VaginitisVaginitis
Vaginitis
 
Vaginal discharge
Vaginal dischargeVaginal discharge
Vaginal discharge
 
Vaginal Discharge
Vaginal DischargeVaginal Discharge
Vaginal Discharge
 
BACTERIAL VAGINOSIS 2021 ppt.pptx
BACTERIAL VAGINOSIS 2021 ppt.pptxBACTERIAL VAGINOSIS 2021 ppt.pptx
BACTERIAL VAGINOSIS 2021 ppt.pptx
 
Development of monoclonal antibodies Workshop
Development of monoclonal antibodies WorkshopDevelopment of monoclonal antibodies Workshop
Development of monoclonal antibodies Workshop
 
Pid by dr shabnam naz
Pid by dr shabnam nazPid by dr shabnam naz
Pid by dr shabnam naz
 
Hiv in pregnancy
Hiv in pregnancyHiv in pregnancy
Hiv in pregnancy
 

More from Ching-wen Lu

「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf
「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf
「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf
Ching-wen Lu
 
最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講 (民眾版)
最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講  (民眾版)最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講  (民眾版)
最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講 (民眾版)
Ching-wen Lu
 
為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf
為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf
為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf
Ching-wen Lu
 
2023.9.6重症安寧.pdf
2023.9.6重症安寧.pdf2023.9.6重症安寧.pdf
2023.9.6重症安寧.pdf
Ching-wen Lu
 
20230818失智共照中心課程.pdf
20230818失智共照中心課程.pdf20230818失智共照中心課程.pdf
20230818失智共照中心課程.pdf
Ching-wen Lu
 
預立醫療照護諮商(advance care planning): 重新想像 醫病信賴關係 的起點
預立醫療照護諮商(advance care planning):重新想像醫病信賴關係的起點預立醫療照護諮商(advance care planning):重新想像醫病信賴關係的起點
預立醫療照護諮商(advance care planning): 重新想像 醫病信賴關係 的起點
Ching-wen Lu
 
在宅善終的 最後一哩路: 居家安寧 Can Help!
在宅善終的 最後一哩路: 居家安寧 Can Help!在宅善終的 最後一哩路: 居家安寧 Can Help!
在宅善終的 最後一哩路: 居家安寧 Can Help!
Ching-wen Lu
 
敘事醫學:一位前衛生所醫師的經驗.pdf
敘事醫學:一位前衛生所醫師的經驗.pdf敘事醫學:一位前衛生所醫師的經驗.pdf
敘事醫學:一位前衛生所醫師的經驗.pdf
Ching-wen Lu
 
20210712 糖尿病個案報告
20210712 糖尿病個案報告20210712 糖尿病個案報告
20210712 糖尿病個案報告
Ching-wen Lu
 
2021.4.29 loneliness and depression in the elderly the role of social network...
2021.4.29 loneliness and depression in the elderly the role of social network...2021.4.29 loneliness and depression in the elderly the role of social network...
2021.4.29 loneliness and depression in the elderly the role of social network...
Ching-wen Lu
 
using narrative analysis to understand the combined use of complementary ther...
using narrative analysis to understand the combined use of complementary ther...using narrative analysis to understand the combined use of complementary ther...
using narrative analysis to understand the combined use of complementary ther...
Ching-wen Lu
 
2021.03.23 住院醫師搞工會:搞什麼東西?
2021.03.23 住院醫師搞工會:搞什麼東西?2021.03.23 住院醫師搞工會:搞什麼東西?
2021.03.23 住院醫師搞工會:搞什麼東西?
Ching-wen Lu
 
Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...
Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...
Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...
Ching-wen Lu
 
Lifestyle medicine ch13 physical fitness evaluation
Lifestyle medicine ch13 physical fitness evaluationLifestyle medicine ch13 physical fitness evaluation
Lifestyle medicine ch13 physical fitness evaluation
Ching-wen Lu
 
生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa
生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa
生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa
Ching-wen Lu
 
醫療化:從出生至死亡2020.11.03@nhu
醫療化:從出生至死亡2020.11.03@nhu醫療化:從出生至死亡2020.11.03@nhu
醫療化:從出生至死亡2020.11.03@nhu
Ching-wen Lu
 
Oral frailty and spt
Oral frailty and sptOral frailty and spt
Oral frailty and spt
Ching-wen Lu
 
Palliative in acs 2ed
Palliative in acs 2edPalliative in acs 2ed
Palliative in acs 2ed
Ching-wen Lu
 
20200728 cga ch1
20200728 cga ch120200728 cga ch1
20200728 cga ch1
Ching-wen Lu
 
20200922 cga ch3
20200922 cga ch320200922 cga ch3
20200922 cga ch3
Ching-wen Lu
 

More from Ching-wen Lu (20)

「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf
「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf
「斷食」真可「善終」? 圍繞 VSED(自主停止飲食) 討論的社會效應 .pdf
 
最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講 (民眾版)
最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講  (民眾版)最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講  (民眾版)
最後一哩路我陪你 末期病人照顧 20240521 外埔家照據點演講 (民眾版)
 
為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf
為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf
為什麼醫療需要社會學?淺談質性研究與敘事醫學.pdf
 
2023.9.6重症安寧.pdf
2023.9.6重症安寧.pdf2023.9.6重症安寧.pdf
2023.9.6重症安寧.pdf
 
20230818失智共照中心課程.pdf
20230818失智共照中心課程.pdf20230818失智共照中心課程.pdf
20230818失智共照中心課程.pdf
 
預立醫療照護諮商(advance care planning): 重新想像 醫病信賴關係 的起點
預立醫療照護諮商(advance care planning):重新想像醫病信賴關係的起點預立醫療照護諮商(advance care planning):重新想像醫病信賴關係的起點
預立醫療照護諮商(advance care planning): 重新想像 醫病信賴關係 的起點
 
在宅善終的 最後一哩路: 居家安寧 Can Help!
在宅善終的 最後一哩路: 居家安寧 Can Help!在宅善終的 最後一哩路: 居家安寧 Can Help!
在宅善終的 最後一哩路: 居家安寧 Can Help!
 
敘事醫學:一位前衛生所醫師的經驗.pdf
敘事醫學:一位前衛生所醫師的經驗.pdf敘事醫學:一位前衛生所醫師的經驗.pdf
敘事醫學:一位前衛生所醫師的經驗.pdf
 
20210712 糖尿病個案報告
20210712 糖尿病個案報告20210712 糖尿病個案報告
20210712 糖尿病個案報告
 
2021.4.29 loneliness and depression in the elderly the role of social network...
2021.4.29 loneliness and depression in the elderly the role of social network...2021.4.29 loneliness and depression in the elderly the role of social network...
2021.4.29 loneliness and depression in the elderly the role of social network...
 
using narrative analysis to understand the combined use of complementary ther...
using narrative analysis to understand the combined use of complementary ther...using narrative analysis to understand the combined use of complementary ther...
using narrative analysis to understand the combined use of complementary ther...
 
2021.03.23 住院醫師搞工會:搞什麼東西?
2021.03.23 住院醫師搞工會:搞什麼東西?2021.03.23 住院醫師搞工會:搞什麼東西?
2021.03.23 住院醫師搞工會:搞什麼東西?
 
Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...
Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...
Elder Abuse in the COVID-19 Era. / Informal caregivers’ perspectives on healt...
 
Lifestyle medicine ch13 physical fitness evaluation
Lifestyle medicine ch13 physical fitness evaluationLifestyle medicine ch13 physical fitness evaluation
Lifestyle medicine ch13 physical fitness evaluation
 
生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa
生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa
生命末期的在地道德世界: 對安寧共照個管師與家庭會議的考察2020.11.29 tsa
 
醫療化:從出生至死亡2020.11.03@nhu
醫療化:從出生至死亡2020.11.03@nhu醫療化:從出生至死亡2020.11.03@nhu
醫療化:從出生至死亡2020.11.03@nhu
 
Oral frailty and spt
Oral frailty and sptOral frailty and spt
Oral frailty and spt
 
Palliative in acs 2ed
Palliative in acs 2edPalliative in acs 2ed
Palliative in acs 2ed
 
20200728 cga ch1
20200728 cga ch120200728 cga ch1
20200728 cga ch1
 
20200922 cga ch3
20200922 cga ch320200922 cga ch3
20200922 cga ch3
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfTest bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
rightmanforbloodline
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Kunj Vihari
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
DrGirishJHoogar
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
KULDEEP VYAS
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIESLOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
ShraddhaTamshettiwar
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfTest bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIESLOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 

Gyn bv 20200214: Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure

  • 1. Journal Reading Presenter: FM R2盧敬文 Supervisor: VS 何宗錦 2020.02.14
  • 2. • vaginal microbiota (VMB) • vaginal dysbiosis • bacterial vaginosis (BV) characterized by a reduction of lactobacilli and an increase of other anaerobes • bacterial pathobionts (Proteobacteria, streptococci, staphylococci, and enterococci) • Candida albicans • Trichomonas vaginalis
  • 3. • Vaginal dysbiosis  pelvic inflammatory disease, HIV acquisition, and adverse pregnancy outcomes. • BV is diagnosed by: Nugent scoring of vaginal Gram stains or by the Amsel criteria. • BV is treated with antibiotics • recurrence rates are high https://en.wikipedia.org/wiki/Nugent_score
  • 4. • Metronidazole is a nitroimidazole class drug. • Culture studies have shown that lactobacilli are not sensitive to metronidazole. High recurrence rate? • Hypothesized: due to vaginal mucosal biofilm formation by G. vaginalis and other BV-associated anaerobes
  • 5. Materials and Methods • Rinda Ubuzima research clinic in Kigali, Rwanda, in 2015 • women at high risk of BV/T. vaginalis • in the last 12 months • more than 1 sex partner • having been treated for BV and/or a sexually transmitted infection • BV-positive and/or T. vaginalis -positive • treated with 7 days of 500 mg generic oral metronidazole, BID • Posttreatment visit within 3 days after treatment completion
  • 6. Diagnostic procedures • BV was diagnosed by • Gram stain Nugent scoring a score of 0-3 was considered optimal, 4-6 intermediate microbiota, and 7-10 BV • modified Amsel criteria defined as the presence of 2/3 criteria: • vaginal pH >4.5 • positive whiff test • and/or > 20% clue cells 黃珮茹、林益卿。常見陰道炎診斷與治療。家庭醫學與基層醫療。第三十一卷,第五期。
  • 7. Molecular VMB testing • DNA was extracted from 1 swab per woman per visit • The V3-V4 region of 16S rRNA genes were amplified and sequenced • The panbacterial 16S rRNA gene copy concentration per sample was determined http://www.yourgene.com.tw/content/messagess/contents/655643254701452640/ 16S 核糖體 RNA (16S rRNA) 在演化過程中,改變的程度相當 的低,大多數 16S rRNA 其中有 V1~V9 共 9 個高度變異區域 (High Variable Regions,HVRs) 透過選擇其中高變區的序列,進行 PCR 專一性增幅放大, 經過定序,將序列作為分類與鑑定環境或生物體內微生物 之種類與群落
  • 8. Statistical analyses • VMB characteristics pre- and posttreatment were compared • all women (N=68), • women stratified by treatment success/failure(n=55) • Pretreatment C. trachomatis/N. gonorrhoeae status(N=67) • Received another antibiotic in addition to metronidazole at the pretreatment visit or not (N=68) • having reported unusual vaginal discharge pretreatment or not(N=68)
  • 9. Ethical statement • Written informed consent provided • approved by the National Ethics Committee of Rwanda • and the University of Liverpool Research Ethics Subcommittee for Physical Interventions.
  • 11.
  • 13. 82.4%: BV alone 2.9%: T. vaginalis alone 14.7%: both BV and T. vaginalis 38.2%: Ongoing C. trachomatis and/or N. Gonorrhoeae infection
  • 14. mean bacterial group relative abundances
  • 15. Pre- and posttreatment 16S microbiota data shift toward increased relative abundance of lactobacilli  decreased relative abundances of several BV anaerobes
  • 16. Total bacterial concentration Total lactobacilli Total BV-anaerobes Total pathobionts But interindividual variability was high Most variability
  • 17. • Participants with treatment failure as defined by Nugent scoring • posttreatment Lower mean lactobacilli relative abundance, smaller decreases in mean total bacteria and BV-anaerobes concentrations, less often a lactobacilli-dominated VMB type, • pretreatment Greater mean pathobionts concentration
  • 18. • Successfully treated participants: significant decreases in the mean concentrations of all 8 common BV anaerobes • unsuccessfully treated participants: not decreases in G. vaginalis and BVAB1 • not identify any statistically significant sociodemographic or biological correlates of treatment failure • except for pathobionts concentration pretreatment
  • 19. Discussion • cure rate of 7-day oral metronidazole treatment by Nugent scoring only 54.5%. • Treatment failure associated with: • greater levels of pretreatment Gardnerella vaginalis or pathobionts • not with sociodemographic factors.
  • 20. • unknown which concentrations of which pathobionts in the vagina should be treated to prevent complications • metronidazole treatment  not change the pathobionts concentration  increase the relative abundance • Greater pretreatment pathobionts concentration  increased likelihood of treatment failure
  • 21. Results of the study in context of what is known • The extent of BV-anaerobes reduction was more modest than expected • lactobacilli are not sensitive to Metronidazole • Women with a pretreatment VMB type containing a relative abundance of >50% G. vaginalis, compared with <50% more likely to continue to have a dysbiotic VMB type posttreatment • CRISPR-genes may protect the bacteria against metronidazole.
  • 22. Research and clinical implications • vaginal biofilm disrupting treatment? • adjuvant therapy with lactobacilli-based live biotherapeutics? • treatment with drugs that specifically target all G. vaginalis clades? • diagnostic tests to determine the presence of a biofilm or concentrations of G. vaginalis  are not yet available
  • 23. Strengths and limitations of the study • limited generalizability of the results to lower risk and non-African populations • lack of vaginal biofilm detection • Strength: used multiple laboratory and analytic methods